Indication
Essential Thrombocytosis
2 clinical trials
4 products
Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
RuxolitinibProduct
PelabresibClinical trial
Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) InhibitionStatus: Recruiting, Estimated PCD: 2029-08-22
Product
TalazoparibProduct
pacritinib